Working... Menu

Rifaximin in Fatty Liver Disease (RiFL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01355575
Recruitment Status : Terminated (Review of primary endpoint data by study Investigators concluded no further patients required.)
First Posted : May 18, 2011
Last Update Posted : October 17, 2012
National Health Service, United Kingdom
Information provided by (Responsible Party):
Imperial College London

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : September 2012
  Actual Study Completion Date : September 2012
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 14, 2015
April 28, 2015
2 November 10, 2016
January 6, 2017
3 April 9, 2019